Navigation Links
Groundbreaking Treatments, Innovative Prevention Strategies and New Insights on Impact of Lifestyle Factors on Digestive Health Presented at the American College of Gastroenterology's 76th Annual Meeting
Date:10/31/2011

WASHINGTON, Oct. 31, 2011 /PRNewswire-USNewswire/ -- Many of the world's preeminent gastroenterologists have convened this week for the American College of Gastroenterology's (ACG) 76th Annual Scientific Meeting at the Gaylord National Hotel and Conference Center at the National Harbor to review the latest scientific advances in gastrointestinal research, treatment of digestive diseases and clinical practice management.

Groundbreaking treatments such as fecal microbiota transplantation for serious gastrointestinal conditions like antibiotic-associated diarrhea and inflammatory bowel disease; innovative prevention strategies for a host of GI-related health conditions including hepatitis C and colorectal cancer; new insights on the relationship between adult irritable bowel syndrome (IBS) and childhood trauma and the impact lifestyle factors like smoking and alcohol consumption have on digestive health, are among the highlights of this year's scientific presentations.

A press kit with highlights of important new science presented at the meeting is available online at the ACG Web site www.acg.gi.org/media/press.asp

Highlights from this year's ACG Scientific Meeting include:

Antibiotics May Not Be Only Cause of Community-Acquired C. difficile Infection;
Patient's Place of Residence May Allow for "On-Admission" Prediction Model of Disease Severity
Antibiotics may not be the only risk factor associated with community–acquired Clostridium difficile infection, indicating that other undefined causes of the potentially life-threatening infection may exist and could also predict whether or not a patient will require hospitalization, according to researchers from the Mayo Clinic College of Medicine in Rochester, MN.

A separate study by researchers from Winthrop University Hospital, in Mineola, New York, who assessed predictor
'/>"/>

SOURCE American College of Gastroenterology
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Groundbreaking Approach to Predicting Cancer Patients Response to Treatment Featured in Science Magazine
2. Ventana Medical Systems, Inc. Introduces Groundbreaking Laboratory Workflow Integration
3. Pharmaceutical Industry Leaders to Tackle Groundbreaking Challenges, Opportunities for Pharma & Biotech at Elite Event
4. Femasys and Norgenix Announce Distribution Agreement for Groundbreaking New Device for Infertility Diagnosis
5. Groundbreaking Report Details the New $80 Billion Accountable-Care Market
6. International Dyslexia Association Announces Groundbreaking Parent Membership Initiative in Response to 40,000 Annual Inquiries
7. Newborn Possibilities Fund Awards Grant to Georgia Health Sciences University Foundation to Support Groundbreaking Pediatric Research
8. Glenveigh Medical and Monica Healthcare Announce Distribution Agreement for Groundbreaking FDA Cleared Wireless Fetal Monitoring System
9. SinoFresh Healthcare, Inc. Takes Groundbreaking Products to Europe
10. Groundbreaking Study Showed Bayers Advantage Multi® for Dogs (imidacloprid + moxidectin) Topical Solution was the only Heartworm Preventive Tested That Demonstrated 100 Percent Efficacy against the Challenging MP3 Strain
11. Pharma Industry Leaders to Reveal Hottest, Latest Trends for Pharma & Biotech at Groundbreaking Event
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... 2014  Array BioPharma Inc. (Nasdaq: ... Chief Executive Officer, Ron Squarer , ... The public is welcome to participate in ... BioPharma website:  www.arraybiopharma.com .Event: Piper Jaffray 2014 ... Time Location: Palace Hotel, New York CityEvent:Oppenheimer ...
(Date:11/26/2014)... LONDON , Nov. 25, 2014 Amgen ... AZN ) today announced that AMAGINE-2 TM , a pivotal, ... more than 1,800 patients with moderate-to-severe plaque psoriasis, met its ... and placebo at week 12. Brodalumab 210 mg given every ... shown to be superior to Stelara on the primary endpoint ...
(Date:11/26/2014)... and HERZLIYA PITUACH, Israel, Nov. 25, 2014 ... Company"), a clinical stage biopharmaceutical company that engages ... for the treatment of inflammatory diseases and cancer, ... underwritten public offering of 3,450,000 units, with each ... common stock, par value $0.0001 per share, and ...
Breaking Medicine Technology:Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 2Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 3Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 4Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 5Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 6Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 7Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 8Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 9Amgen And AstraZeneca Announce Positive Results From Third And Final Pivotal Phase 3 Study Of Brodalumab In Patients With Moderate-To-Severe Plaque Psoriasis 10Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 2Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 3Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 4Immune Pharmaceuticals Inc. Announces Closing Of Public Offering Of Common Stock And Warrants 5
... OSLO, Norway, October 31, 2011 Oslo ... oncology. The true strength of the Norwegian cluster lies ... than the ones available to cancer patients today. ... cluster within the field of oncology, dedicated to accelerating ...
... Inc. (ARKRAY) announced today that the GLUCOCARD® Vital and ... (DoD) Uniform Formulary.  The DoD Pharmacy and Therapeutic committee ... 01 Blood Glucose Meters as the first and second ... of service as noted by the Uniform Formulary Beneficiary ...
Cached Medicine Technology:Expanding Norwegian Cluster of Excellence Dedicated to Oncology 2Expanding Norwegian Cluster of Excellence Dedicated to Oncology 3ARKRAY's GLUCOCARD® Vital and 01 Blood Glucose Meters are now on the Department of Defense Uniform Formulary. 2
(Date:11/27/2014)... (PRWEB) November 27, 2014 Now that ... season has officially launched, Emassagechair.com has announced ... Monday Discount Event. , Negotiating on behalf of ... top massage chair brands, Emassagechair.com has generated significant buzz ... deals and biggest discounts yet. , Shoppers are excited ...
(Date:11/27/2014)... 27, 2014 VogueQueen.com is making every ... ladies across the world. As the premier online supplier ... is proud to release a huge selection of sexy ... outfits, it is also providing many beautiful styles in ... gowns at discounted prices. , “VogueQueen.com hopes to ...
(Date:11/27/2014)... 27, 2014 Developers and plugin specialist of ... entitled ProPip, taking FCPX to the next level. , “ProPip ... a few clicks of a mouse,” said Christina Austin, CEO ... our users will appreciate.” , With ProPip users can show ... possibilities truly endless. ProPip is great for commentaries, news casting, ...
(Date:11/27/2014)... HealthPostures, a leading national designer ... announced that it has entered into a new ... will put HealthPostures' products into central Indiana’s premiere ... to having its products sold through Commercial Office ... with the business decision makers in the Indianapolis ...
(Date:11/27/2014)... At The Little Gym, we know ... as no surprise when a recent study confirmed that ... The Journal of Pediatrics found that “Promoting ... during the school years may be important not only ... study monitored two groups of children; those that were ...
Breaking Medicine News(10 mins):Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 2Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 3Health News:Emassagechair.com is Excited to Announce Their Biggest Discount Event of the Year, Starting the Day After Thanksgiving and Lasting Through The Holiday Weekend. 4Health News:A New Collection of Sexy Prom Dresses Has Been Released by the Reliable Online Supplier VogueQueen.com 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 2Health News:Pixel Film Studios released ProPip plugin Exclusively for Final Cut Pro X 3Health News:Ergonomics Manufacturer Announces New Partnership with Office Supply Dealer 2
... have, for the first time, taken adult stem cells and ... human jaw.They say the groundbreaking work may one day //lead ... suffer from temporomandibular disorders. ,The study started with ... these cells can be coaxed to become any other type ...
... the last half century, and officials at the ... be diagnosed with it this year.,The study, which analyzed ... ages of 30 and 50,// found what the researchers ... tanning can be dangerous to healthy skin. ,Melanoma ...
... and observational studies previously conducted in elderly populations ... were performed before intracoronary stents and use of ... Dr. Hanoch Hod, of Chaim Sheba Medical //Center ... consecutive patients aged 70 or older treated for ...
... hormone may help patients in treating a rare disorder ... metabolic abnormalities.The study's author found that the results of ... role of leptin in common metabolic conditions such as ... her colleagues found that a lab-engineered version of leptin, ...
... control to limit women's periods ,Seasonale, a new drug ... reduce the number of women's periods to four a year ... pills, but for longer spans of time.// ,Seasonale ... ,"For women who desire prevention of pregnancy and are comfortable ...
... milk chocolate, which is most commonly used in candy ... They found the same discouraging result among patients who ... suggest that milk and other dairy products somehow discourage ... chocolate. Only subjects who ate dark chocolate showed a ...
Cached Medicine News:Health News:Solarium use is associated with an increased risk of skin cancer 2Health News:Angioplasty plus stenting better than thrombolysis for elderly patients with AMI, 2Health News:Obesity Hormone -' Leptin' may treat Metabolic Disorder 2Health News:New birth control to limit women's periods 2Health News:When it comes to health, all chocolates not the same. 2
This radiolucent One-piece fixator permits independent mechanical adjustments of the following: Distraction/Compression, Dorsal/Palmar Translation, Radial/Ulnar Translation, Flexion/Extension....
Provides basic reduction capabilities for angulation, rotation and length. Ball joint design offers fracture reduction in all planes....
The Medium External Fixator has a medium Combination Clamp that connects rod to rod or pin to rod as well as a Medium Multi-Pin Clamp that connects pins to rods allowing parallel pin placement....
... the Pennig Minifixator, combines the advantage of secure ... tissue dissection is not necessary, since in general, ... fixation in the hand has required bridging of ... (Asche and Burny) because of the design of ...
Medicine Products: